The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Is The Estimated Growth In Market Size Of The Inhaler Corticosteroid Device Market During 2026–2030?
The inhaler corticosteroid device market size has seen strong growth in recent years. It is anticipated to increase from $16.83 billion in 2025 to $17.98 billion in 2026, progressing at a compound annual growth rate (CAGR) of 6.8%. The historical growth can be linked to the rising prevalence of asthma and COPD, enhanced awareness regarding inhaler therapies, governmental programs for respiratory health, developments in metered-dose inhalers, and the expansion of hospital and homecare facilities.
The inhaler corticosteroid device market is projected to experience robust expansion over the coming years. This market is forecast to reach $23.18 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.6%. This anticipated growth during the forecast period can be primarily attributed to factors such as the incorporation of AI and IoT into inhaler technologies, the creation of environmentally friendly inhalers, the widening reach of telehealth services, customized medication dispensing, and increasing demand from developing economies. Key trends anticipated during this period encompass the adoption of smart inhalers, tailored dosage administration, remote monitoring facilitated by telehealth, sustainable and eco-conscious device designs, and innovative aerosol delivery methods.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25794&type=smp
Which Growth Drivers Are Expected To Support The Inhaler Corticosteroid Device Market Forward?
A growing incidence of respiratory illnesses is anticipated to drive the expansion of the inhaler corticosteroid device market in the coming period. Respiratory diseases refer to diverse conditions that affect the lungs and airways, making it challenging for individuals to breathe correctly and efficiently. The occurrence of respiratory diseases is increasing due to escalating air pollution, which exposes people to harmful particles that damage lung tissue and trigger chronic conditions such as asthma and bronchitis. Inhaler corticosteroid devices are utilized to manage respiratory diseases by delivering anti-inflammatory medication directly into the lungs, thereby helping to lessen inflammation and improve breathing. For instance, in June 2025, information from the Office for Health Improvement and Disparities, a UK-based government department, revealed that in the financial year ending 2024, England recorded 854,922 emergency hospital admissions for respiratory diseases. This equated to a rate of 1,428 (ranging from 1,424 to 1,432) per 100,000 population, indicating a 7% increase compared to the previous year. Therefore, the rising prevalence of respiratory diseases is fueling the growth of the inhaler corticosteroid device market.
What Segment Types Are Included In The Inhaler Corticosteroid Device Market Analysis?
The inhaler corticosteroid device market covered in this report is segmented –
1) By Product Type: Metered-Dose Inhalers, Dry Powder Inhalers, Soft Mist Inhalers
2) By Formulation Type: Fluticasone Propionate, Budesonide, Beclomethasone, Mometasone Furoate
3) By Distribution Channel: Online Pharmacies, Retail Pharmacies, Direct Sales, Hospital Pharmacies
4) By Application: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Other Applications
5) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Metered-Dose Inhalers: Conventional Metered-Dose Inhalers, Breath-Actuated Metered-Dose Inhalers, Spacer-Integrated Metered-Dose Inhalers
2) By Dry Powder Inhalers: Single-Dose Dry Powder Inhalers, Multi-Dose Dry Powder Inhalers, Reservoir Dry Powder Inhalers
3) By Soft Mist Inhalers: Manual Soft Mist Inhalers, Battery-Operated Soft Mist Inhalers
Which Trends Are Contributing To Changes In The Inhaler Corticosteroid Device Market?
Leading companies in the inhaler corticosteroid device market are concentrating on introducing novel solutions, such as rescue inhalers that combine albuterol and budesonide, to improve treatment efficacy and offer patients a more convenient, dual-action therapy within a single device. An inhaler integrating albuterol and budesonide functions as a dual-action rescue inhaler, delivering both a bronchodilator (albuterol) for rapid airway opening and a corticosteroid (budesonide) to lessen inflammation, thereby providing quick symptom relief and sustained asthma management in one device. For instance, in January 2024, AstraZeneca PLC, a UK-based pharmaceutical industry company, launched AIRSUPRA, which is the first and only FDA-approved rescue inhaler combining albuterol and budesonide for adults with asthma. This inhaler is formulated for as-needed administration to both relieve acute bronchoconstriction symptoms and decrease airway inflammation, consequently reducing the risk of severe asthma exacerbations. It signifies a fresh approach by merging a short-acting beta2-agonist (albuterol) with an inhaled corticosteroid (budesonide) in a single inhaler, with its approval being based on clinical trials that demonstrated its superior efficacy over albuterol alone in preventing asthma attacks.
Which Organizations Are Involved In The Inhaler Corticosteroid Device Market?
Major companies operating in the inhaler corticosteroid device market are AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Teijin Pharma Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma Limited, Chiesi Farmaceutici S.p.A., Cipla Limited, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Mundipharma International Limited, Lupin Limited, Zydus Lifesciences Limited, Recipharm AB, Glenmark Pharmaceuticals Limited, Orion Corporation, Beximco Pharmaceuticals Limited, PARI Medical Holding GmbH
Access The Complete Inhaler Corticosteroid Device Market Report:
https://www.thebusinessresearchcompany.com/report/inhaler-corticosteroid-device-global-market-report
Which Area Represents The Largest Portion Of The Inhaler Corticosteroid Device Market?
North America was the largest region in the inhaler corticosteroid device market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inhaler corticosteroid device market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access a Inhaler Corticosteroid Device Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/report/inhaler-corticosteroid-device-global-market-report
Browse Through More Reports Similar to the Global Inhaler Corticosteroid Device Market 2026, By The Business Research Company
Implantable Infusion Pumps Market Report 2026
https://www.thebusinessresearchcompany.com/report/implantable-infusion-pumps-global-market-report
Intravenous Infusion Pumps Market Report 2026
https://www.thebusinessresearchcompany.com/report/intravenous-infusion-pumps-global-market-report
Ambulatory Iv Infusion Pumps Market Report 2026
https://www.thebusinessresearchcompany.com/report/ambulatory-iv-infusion-pumps-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model